MyBPC3: A Potential Drug Target and Biomarker for Parkinson's disease

Target Name: MYBPC3

NCBI ID: G4607

MYBPC3

MyBPC3: A Potential Drug Target and Biomarker for Parkinson's disease

Parkinson's disease is a common neurodegenerative disease characterized by muscle rigidity, decreased movement, and decreased facial expressions. At present, the treatment of Parkinson's disease mainly relies on drug treatment, including levodopa, compound levodopa, and bromocriptine. However, these drugs still have many side effects and unmet needs in treating Parkinson's disease. Therefore, researchers are constantly searching for new treatments and drug targets.

MYBPC3 is a protein whose expression is upregulated in patients with Parkinson's disease. Through the study of MYBPC3, researchers found that MYBPC3 is up-regulated in patients with Parkinson's disease, and the expression level is positively correlated with the severity and progression rate of the disease. In addition, MYBPC3 is also associated with clinical manifestations and drug response of Parkinson's disease.

Currently, MYBPC3 has become a research hotspot in the field of Parkinson's disease. Researchers are exploring MYBPC3 as a potential drug target for Parkinson's disease and looking for drug molecules that may be related to it. At the same time, researchers also hope to provide new ideas and methods for the treatment of Parkinson's disease by studying MYBPC3.

In conclusion, MYBPC3 is a potential drug target for Parkinson's disease. By studying MYBPC3, we can better understand the pathogenesis of Parkinson's disease and provide new treatments and drugs for Parkinson's disease.

Protein Name: Myosin Binding Protein C3

Functions: Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. It may modulate muscle contraction or may play a more structural role

The "MYBPC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYBPC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets